The estimated Net Worth of Mark A Augusti is at least $9.15 Million dollars as of 7 May 2022. Mr. Augusti owns over 22,396 units of Conformis stock worth over $5,500,221 and over the last 10 years he sold CFMS stock worth over $794,393. In addition, he makes $2,853,750 as President, Chief Executive Officer, and Director at Conformis.
Mark has made over 24 trades of the Conformis stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 22,396 units of CFMS stock worth $10,302 on 7 May 2022.
The largest trade he's ever made was selling 104,065 units of Conformis stock on 2 November 2020 worth over $68,683. On average, Mark trades about 15,726 units every 37 days since 2014. As of 7 May 2022 he still owns at least 2,433,726 units of Conformis stock.
You can see the complete history of Mr. Augusti stock trades at the bottom of the page.
Mark A. Augusti serves as President, Chief Executive Officer, Director of the Company. Mr. Augusti was Integra LifeSciences Corporation’s corporate vice president, and president of Orthopedics and Tissue Technologies. Mr. Augusti was responsible for the management of the Orthopedics and Tissue Technologies global division, which includes extremity implants, tissue products, and the Private Label business. His responsibilities included U.S. commercial leadership, global portfolio management, evaluation of corporate development opportunities and overall strategic direction. Prior to joining Integra in 2014, Mr. Augusti served as chief executive officer at Bioventus LLC from May 2012 to August 2013, and was a member of Bioventus’ board of directors during the same period. Prior to that, Mr. Augusti spent nine years with Smith & Nephew from April 2003 to April 2012 in a series of leadership roles, including President of Smith & Nephew’s Biologic Division, where he was appointed to lead Smith & Nephew’s new biologics initiative. He also served as Smith & Nephew’s president of the Orthopaedic Trauma & Clinical Therapies global business and senior vice president and general manager of the Trauma business. From 1987 to 2000, he spent 13 years at GE Medical Systems, where he held various sales, marketing and strategic management roles, both in the U.S. and internationally. Mr. Augusti received his M.B.A. from the UCLA Anderson School of Management, and his B.S. in Computer Science and Economics from Duke University. Our board of directors nominated Mr. Augusti to stand for election as a class I director at the Annual Meeting. If elected, Mr. Augusti’s term as a class I director will expire at our 2022 Annual Meeting of Stockholders.
As the President, Chief Executive Officer, and Director of Conformis, the total compensation of Mark Augusti at Conformis is $2,853,750. There are no executives at Conformis getting paid more.
Mark Augusti is 54, he's been the President, Chief Executive Officer, and Director of Conformis since 2016. There are 8 older and 6 younger executives at Conformis. The oldest executive at Conformis Inc. is Kenneth Fallon, 80, who is the Independent Chairman of the Board.
Mark's mailing address filed with the SEC is C/O CONFORMIS, INC., 600 TECHNOLOGY PARK DRIVE, BILLERICA, MA, 01821.
Over the last 9 years, insiders at Conformis have traded over $10,769,806 worth of Conformis stock and bought 583,200 units worth $267,840 . The most active insiders traders include Capital Management Llcchris..., Philipp Lang, and Mark A Augusti. On average, Conformis executives and independent directors trade stock every 21 days with the average trade being worth of $122,083. The most recent stock trade was executed by Mark A Augusti on 7 May 2022, trading 22,396 units of CFMS stock currently worth $10,302.
our mission patients vary in more ways than gender, race, and size. at conformis, we believe that optimizing implant fit and performance requires a patient-specific approach. our mission is to provide best-in-class, patient-specific implants and instrumentation that offer unique advantages over traditional orthopedic implants. we start with a simple idea: make the implant fit the patient rather than forcing the patient to fit the implant. our implants are individually sized and shaped to fit to each patient’s unique anatomy, providing precise anatomic fit and preserving healthy tissue. our disposable, patient-specific cutting and placement guides also eliminate many of the tools required for traditional orthopedic surgery and simplify surgical technique. by combining our personalized implants with our unique instrumentation, a surgeon is able to provide a custom solution that preserves more of a patient’s joint and minimizes surgical trauma. our company conformis, inc. is a privately h
Conformis executives and other stock owners filed with the SEC include: